XML 24 R6.htm IDEA: XBRL DOCUMENT v3.6.0.2
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating activities      
Net loss $ (31,358) $ (33,704) $ (29,373)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 3,511 2,254 1,175
Bad debt expense 68 105 54
Loss on disposal of property and equipment 12 0 0
Genzyme co-promotion fee amortization (948) (1,897) (2,269)
Stock-based compensation 6,378 5,602 3,548
Conversion of accrued interest to long-term debt 385 0 0
Amortization of debt discount and issuance costs 173 46 97
Interest on debt balloon payment and prepayment penalty 206 79 81
Changes in operating assets and liabilities:      
Accounts receivable (5,321) (558) (1,961)
Supplies inventory 292 (71) (1,129)
Prepaid expenses and current other assets (415) 304 (38)
Other assets 25 (42) (46)
Accounts payable (1,441) (3,546) 1,874
Accrued liabilities and deferred rent 451 4,463 355
Net cash used in operating activities (27,982) (26,965) (27,632)
Investing activities      
Purchases of property and equipment (4,210) (6,165) (2,024)
Cash remitted for acquisition, net of cash received 0 0 (6,916)
Change in restricted cash (2) (533) (70)
Net cash used in investing activities (4,212) (6,698) (9,010)
Financing activities      
Proceeds from the issuance of long-term debt, net of debt issuance costs 24,452 0 0
Proceeds from issuance of common stock in a private placement, net of issuance costs 0 37,258 0
Proceeds from issuance of common stock in a public offering, net of issuance costs 31,949    
Commissions and issuance costs relating to initial public offering 0 0 (129)
Payment of long-term debt (5,000) 0 0
Payment of end-of-term debt obligation and prepayment penalty (288) 0 (110)
Payment of deferred stock offering costs 0 (247) 0
Proceeds from the exercise of common stock options and employee stock purchases 1,216 722 675
Net cash provided by financing activities 52,329 37,733 436
Net increase (decrease) in cash and cash equivalents 20,135 4,070 (36,206)
Cash and cash equivalents at beginning of period 39,084 35,014 71,220
Cash and cash equivalents at end of period 59,219 39,084 35,014
Supplementary cash flow information of non-cash investing and financing activities:      
Fair value of common stock issued for acquisition 0 0 10,078
Non-cash issuance of long-term debt 0 0 5,000
Non-cash repayment of long-term debt 0 0 (5,000)
Net receivable for reimbursement of public offering issuance costs 144 0 0
Purchases of property and equipment included in accounts payable and accrued liabilities 363 1,825 383
Issuance of common stock from the non-cash exercise of common stock warrants 0 0 187
Supplementary cash flow information:      
Cash paid for interest on debt 2,149 278 307
Cash paid for tax $ 7 $ 22 $ 0